General
Preferred name
testosterone
Synonyms
CPD000058344 ()
testosterone58-22-0 ()
Testosterone-d3 ()
Axiron ()
NSC-9700 ()
Testim ()
Tostran ()
Natesto ()
Vogelxo ()
Fortesta ()
Testoderm tts ()
Testim 1% ()
Androderm ()
Testosterone ciii ()
Virosterone ()
Striant ()
Testogel ()
Testopatch ()
Delatestryl ()
Testoderm ()
Testopel ()
Intrinsa ()
Striant SR ()
Testiculosterone ()
Androgel 1% ()
Androgel ()
Testoral ()
Andropatch ()
Android-t ()
Livensa ()
Homosterone ()
Androlan ()
Testosterone ()
(1,2,6,7-3H)Testosterone ()
P&D ID
PD002847
CAS
58-22-0
67308-98-9
77546-39-5
1050678-68-6
Tags
natural product
drug
drug candidate
endogenous
available
Approved by
FDA
First approval
1972
Drug indication
Osteoporosis
Androgen
Hormone deficiency
Male hormonal deficiency
Drug Status
vet_approved
experimental
withdrawn
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Testosterone is the principal male sex hormone and an anabolic steroid. (GtoPdb)
MOA Testosterone mediates its effects by activating androgen receptors directly or as DHT, or being converted to estradiol which acts as an endogenous lignad on estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT displays an androgenic potency that is about 2.5 times higher than to that of free T. Upon formation, the T-receptor or DHT-receptor complex undergoes a structural change that allows translocation of the complex into the cell nucleus and direct binding to the specific nucleotide sequences of the chromosomal DNA as a transcription factor. These specific nucleotide sequences are also called hormone response elements (HREs) that, when activated, promote transcriptional activity of certain genes responsible for the androgen effects.
Compound Sets
25
Bioprocess diversity set
Cayman Chemical Bioactives
15645
32986
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL386630
ChEMBL Drugs
CHEMBL386630
Concise Guide to Pharmacology 2017/18
2858
Concise Guide to Pharmacology 2019/20
2858
Concise Guide to Pharmacology 2021/22
2858
Concise Guide to Pharmacology 2023/24
2858
DrugBank
DB00624
DB14093
DrugBank Approved Drugs
DB00624
DrugCentral
2607
DrugCentral Approved Drugs
2607
DrugMAP
DM7HUNW
DrugMAP Approved Drugs
DM7HUNW
Guide to Pharmacology
2858
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL386630
Mcule NIBR MoA Box Subset
MCULE-3333652397
NCATS Inxight Approved Drugs
3XMK78S47O
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
NURSA ligand set
nursa/index.jsf?doi=10.1621%2F3XQF26682K
ReFrame library
Withdrawn 2.0
EMA43
External IDs
76
Properties
(calculated by RDKit )
Molecular Weight
288.21
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
0
Ring Count
4
Aromatic Ring Count
0
cLogP
3.88
TPSA
37.3
Fraction CSP3
0.84
Chiral centers
6.0
Largest ring
6.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Biological process
Resipration, oxidative phosphorylation, & mitochondrial targeting
MOA
Androgen Receptor agonist
Androgen Receptor Agonists
Target
Androgen Receptor
Member status
virtual
ATC
G03BA03
Source data